Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in pdcs | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 53 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 10185
Sealed predictions
- CCDC50 in oligodendrocytes, braak-0.12 (p 0.767) → +0.36 (p 0.348)receipt 10192
- CCDC50 in dopamine neurons, braak+0.02 (p 0.964) → +0.27 (p 0.489)receipt 10193
Swarm cases
receipt 10193: CCDC50 in dopamine neurons, braak
- power
- full sample +0.23 (p 0.351, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.346, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.310, n 18). could be the mix.
- skeptic
- leave-one-out range +0.17 to +0.42, sign flips 0; without severely affected donors +0.23 (p 0.351, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCDC50 in dopamine neurons.
case closed: nothing better to follow up.
receipt 10192: CCDC50 in oligodendrocytes, braak
- power
- full sample +0.12 (p 0.646, n 18), 95% CI -0.37 to +0.55. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.17 (p 0.509, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.19 (p 0.439, n 18). could be the mix.
- skeptic
- leave-one-out range +0.01 to +0.27, sign flips 0; without severely affected donors +0.12 (p 0.646, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CCDC50 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts